Asia Pacific HIV Injection Market, By Drug Type (Antiretroviral therapy (ART), Pre-exposure Prophylaxis (PrEP) and Long-acting Injectable), By Distribution Channel, By Country - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Asia Pacific HIV Injection Market size was valued at USD 390.93 million in 2023, expanding at a CAGR of 17.03% from 2024 to 2032.
HIV injections are injectable treatments used for managing HIV, a virus that attacks the body\'s immune system and can progress to AIDS if left untreated. These injections are part of antiretroviral therapy (ART), the standard treatment for HIV. One of the most popular long-acting injectable treatments for HIV is the Cabotegravir and Rilpivirine combination. In 2022, the World Health Organization (WHO) included CAB PrEP in its list of recommended options for HIV prevention, releasing guidelines for its use. By June 2023, CAB PrEP has only received regulatory approval in a few countries, with Australia being the sole country in the Asia-Pacific Region. While HIV infection rates are currently low in many Pacific regions, the potential for rapid spread exists once the virus enters small island populations. Countries such as Bangladesh, East Timor, Japan, Laos, Pakistan, and the Philippines continue to report minimal HIV prevalence, even among high-risk groups. These nations have a unique opportunity to prevent major outbreaks by taking immediate action. The financial support for HIV prevention and treatment, in addition to the existing AUD25 million partnership between UNAIDS and the Australian Government in the Asia Pacific region (2022-2027), signifies an expansion of their ongoing collaboration.
Asia Pacific HIV Injection Market- Market Dynamics
The Asia Pacific HIV Injection Market is anticipated to experience growth due to the increasing prevalence of HIV/AIDS and the growing demand for effective treatment options.
The increasing number of HIV/AIDS cases in the Asia Pacific region is creating a need for effective treatment options, including HIV injections. According to a Chinese medical journal, China has managed to keep the epidemic to less than 0.1% of HIV prevalence by the end of 2017. By October 2020, there were 1.045 million reported cases of people living with HIV/AIDS in China. As awareness about HIV/AIDS grows, there is a rising demand for efficient treatment options. HIV injections, such as long-acting antiretroviral therapies (ART), offer an alternative to daily oral medications, providing convenience and improved treatment adherence. Additionally, advancements in drug delivery systems and the development of long-acting injectables (LAIs) present significant growth opportunities for the market. However, the high cost of HIV injections and treatment may hinder market growth.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
ASIA PACIFIC HIV INJECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
GlaxoSmithKline PLC (GSK)
Gilead Sciences, Inc.
Cipla Limited
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Mylan N.V.
Dr. Reddy\'s Laboratories
Boehringer Ingelheim International GmbH
AbbVie, Inc.
Brii Biosciences Limited
Shionogi & Co., Ltd.
Others
ASIA PACIFIC HIV INJECTION MARKET, BY DRUG TYPE - MARKET ANALYSIS, 2019 - 2032
Antiretroviral therapy (ART)
Pre-exposure Prophylaxis (PrEP)
Long-acting Injectable
ASIA PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacy
Drugs Stores & Retail Pharmacies
Others
ASIA PACIFIC HIV INJECTION MARKET, BY COUNTRY- MARKET ANALYSIS, 2019 - 2032
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
TABLE OF CONTENT
1. Asia Pacific HIV Injection Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Asia Pacific HIV Injection Market Snippet by Drug Type
2.1.2. Asia Pacific HIV Injection Market Snippet by Distribution Channel
2.1.3. Asia Pacific HIV Injection Market Snippet by Country
2.2. Competitive Insights
3. Asia Pacific HIV Injection Key Market Trends
3.1. Asia Pacific HIV Injection Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Asia Pacific HIV Injection Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Asia Pacific HIV Injection Market Opportunities
3.4. Asia Pacific HIV Injection Market Future Trends
4. Asia Pacific HIV Injection Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Asia Pacific HIV Injection Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Asia Pacific HIV Injection Market Landscape
6.1. Asia Pacific HIV Injection Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Asia Pacific HIV Injection Market – By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
7.1.2. Antiretroviral therapy (ART)
7.1.3. Pre-exposure Prophylaxis (PrEP)
7.1.4. Long-acting Injectable
8. Asia Pacific HIV Injection Market – By Distribution Channel
8.1. Overview
8.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
8.1.2. Hospital Pharmacy
8.1.3. Drugs Stores & Retail Pharmacies
8.1.4. Others
9. Asia Pacific HIV Injection Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2. Asia Pacific (APAC)
9.2.1. Overview
9.2.2. Asia Pacific HIV Injection Key Manufacturers in Asia Pacific
9.2.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.2.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.6. India
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.6.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.6.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.7. China
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.7.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.8. Japan
9.2.8.1. Overview
9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.8.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.8.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.9. South Korea
9.2.9.1. Overview
9.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.10. Australia
9.2.10.1. Overview
9.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.10.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.10.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.11. Thailand
9.2.11.1. Overview
9.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.11.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.12. Indonesia
9.2.12.1. Overview
9.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.12.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.13. Philippines
9.2.13.1. Overview
9.2.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.13.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.2.14. Rest of APAC
9.2.14.1. Overview
9.2.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.14.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Asia Pacific HIV Injection Industry
10.1. Competitive Dashboard
10.2. Company Profiles
10.2.1. GlaxoSmithKline PLC (GSK)
10.2.2. Gilead Sciences, Inc.
10.2.3. Cipla Limited
10.2.4. Aurobindo Pharma
10.2.5. Sun Pharmaceutical Industries Ltd.
10.2.6. Mylan N.V.
10.2.7. Dr. Reddy\'s Laboratories
10.2.8. Boehringer Ingelheim International GmbH
10.2.9. AbbVie, Inc.
10.2.10. Brii Biosciences Limited
10.2.11. Shionogi & Co., Ltd.
10.2.12. Others
11. 360 Degree Analyst View
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
